FDA offers Pfizer priority review for tafamidis; Clarivate to merge with Churchill Capital

→ The FDA is giving Pfizer’s tafamidis a quick look over in advance of a likely approval. The agency will give the drug a priority review for transthyretin amyloid cardiomyopathy — offering to lop months off the process. Of course, that presumes the FDA will be back in business soon. 

Clarivate Analytics is merging with Churchill Capital. The combined company will have an enterprise value of $4.2 billion.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->